Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe

BACKGROUND: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region. METHODS: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of puta...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	O. Kirakosyan, M. Reimann, A.B. Andersen, A. Bjarnason, Á. Bakos, A.M. Dyrhol-Riise, A.M. McLaughlin, C. Nita, D. Pieridou, D. Chesov, E.V. Davidavičienė, G. Günther, H. Atshemyan, I. Muylle, I. Solovic, J. Bruchfeld, K. Manika, L. Kuksa, L.R. Codecasa, M. Stosic, M. Skowroński, M.J. Makek, M. Fréchet Jachym, M. Knappik, M. Santin, N. Yatskevich, O. Konstantynovska, O. Akkerman, P. Svetina, P. Viiklepp, R. Duarte, S. Zeynel, T. Togonidze, T. Vasankari, V. Parris, Ş. Özkara, C. Lange, T.T. Brehm
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	International Union Against Tuberculosis and Lung Disease (The Union) 2025-02-01
سلاسل:	IJTLD Open
الموضوعات:	hepatotoxicity drug-induced liver injury hepatitis silibinin ursodeoxycholic acid
الوصول للمادة أونلاين:	https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000002/art00008
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!